Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 18/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717600 | 1.00 | SSTR3 (0.65) | SSTR3CYP2D6KCNH2CACNA1FCACNA1D | |
| SCHEMBL1244098 | 0.80 | SSTR3 (0.44) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6716256 | 0.77 | SSTR3 (0.69) | SSTR3CYP2D6KCNH2 | |
| SCHEMBL6716252 | 0.77 | SSTR3 (0.69) | SSTR3CYP2D6KCNH2 | |
| SCHEMBL12912368 | 0.76 | SSTR3 (0.70) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL13244716 | 0.76 | SSTR3 (0.69) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL13244848 | 0.75 | SSTR3 (0.40) | SSTR3KCNH2 | |
| SCHEMBL3010196 | 0.75 | SSTR3 (0.50) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3014223 | 0.75 | SSTR3 (0.44) | SSTR3KCNH2 | |
| SCHEMBL3010300 | 0.74 | SSTR3 (0.46) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038970-A1 | Beta-carboline compounds | SOCIETE DE CONSEILS DE RECHERCHES ETD' APPLICATION SCIENTIFIQUES, S.A.S. A PARIS, FRANCE CORP. | 2004-02-26 | — | — | US | disclosed |
| US-6586445-B1 | Racemic mixtures of 1,2,3,4-tetra hydro-1-(4-methoxyphenyl)-3 -(4-phenyl-1H-imidazol-2-yl)-9H- pyrido(3,4-b)indole, which bind to somatostatin receptors and block sodium channel modulators; antidiabetic, antiinflammatory agents; diarrhea | Société de Conseils de Recherches et d'Applications Scientifiques, S.A.S. (FR) | 2003-07-01 | — | — | US | disclosed |
| EP-1086101-B1 | BETA-CARBOLINE COMPOUNDS | SOD CONSEILS RECH APPLIC (FR) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038970-A1 | Beta-carboline compounds | SCN1B, SCN2B, CACNA1B | SSTR3 49/4885CYP2D6 2469/4885KCNH2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.